SYRE Stock Summary and Trading Ideas (Spyre Therapeutics | NASDAQ:SYRE)

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Spyre Therapeutics trades on the NASDAQ stock market under the symbol SYRE.

As of April 2, 2026, SYRE stock price declined to $47.58 with 412,835 million shares trading.

SYRE has a beta of 1.77, meaning it tends to be more sensitive to market movements. SYRE has a correlation of 0.21 to the broad based SPY ETF.

SYRE has a market cap of $3.74 billion. This is considered a Mid Cap stock.

Last quarter Spyre Therapeutics reported $0 in Revenue and -$.70 earnings per share. This fell short of revenue expectation by $-111,110 and exceeded earnings estimates by $.04.

The top ETF exchange traded funds that SYRE belongs to (by Net Assets): VTI, IWM, XBI, VXF, IBB.

SYRE has outperformed the market in the last year with a price return of +211.1% while the SPY ETF gained +18.2%. SYRE has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +45.2% and +10.5%, respectively, while the SPY returned -3.6% and -0.6%, respectively.

SYRE support price is $46.89 and resistance is $50.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SYRE shares will trade within this expected range on the day.